Fatty acids cause alterations of human arterial smooth muscle cell proteoglycans that increase the affinity for low-density lipoprotein

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):130-5. doi: 10.1161/01.ATV.0000191659.94059.62. Epub 2005 Oct 20.

Abstract

Objective: The dyslipidemia of insulin resistance, with high levels of albumin-bound fatty acids, is a strong cardiovascular disease risk. Human arterial smooth muscle cell (hASMC) matrix proteoglycans (PGs) contribute to the retention of apoB lipoproteins in the intima, a possible key step in atherogenesis. We investigated the effects of high NEFA levels on the PGs secreted by hASMCs and whether these effects might alter the PG affinity for low-density lipoprotein.

Methods and results: hASMC exposed for 72 hours to high concentrations (800 micromol/L) of linoleate (LO) or palmitate upregulated the core protein mRNAs of the major PGs, as measured by quantitative PCR. Insulin (1 nmol/L) and the PPARgamma agonist rosiglitazone (10 micromol/L) blocked these effects. In addition, high LO increased the mRNA levels of enzymes required for glycosaminoglycan (GAG) synthesis. Exposure to NEFA increased the chondroitin sulfate:heparan sulfate ratio and the negative charge of the PGs. Because of these changes, the GAGs secreted by LO-treated cells had a higher affinity for human low-density lipoprotein than GAGs from control cells. Insulin and rosiglitazone inhibited this increase in affinity.

Conclusions: The response of hASMC to NEFA could induce extracellular matrix alterations favoring apoB lipoprotein deposition and atherogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arteries / cytology
  • Atherosclerosis / metabolism*
  • Cells, Cultured
  • Chondroitin Sulfate Proteoglycans / genetics
  • Chondroitin Sulfate Proteoglycans / metabolism
  • Dyslipidemias / metabolism
  • Glycosyltransferases / metabolism
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Insulin / pharmacology
  • Lectins, C-Type / genetics
  • Lectins, C-Type / metabolism
  • Linoleic Acid / pharmacology*
  • Lipoproteins, LDL / metabolism*
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism*
  • Palmitates / pharmacology
  • Proteoglycans / genetics
  • Proteoglycans / metabolism*
  • RNA, Messenger / metabolism
  • Sulfates / metabolism
  • Sulfotransferases / metabolism
  • Triglycerides / metabolism
  • Versicans

Substances

  • Chondroitin Sulfate Proteoglycans
  • Hypoglycemic Agents
  • Insulin
  • Lectins, C-Type
  • Lipoproteins, LDL
  • Palmitates
  • Proteoglycans
  • RNA, Messenger
  • Sulfates
  • Triglycerides
  • VCAN protein, human
  • Versicans
  • Linoleic Acid
  • Glycosyltransferases
  • Sulfotransferases